We’ve recently updated our valuation analysis.

Veeva Systems Valuation

Is VEEV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VEEV?

Other financial metrics that can be useful for relative valuation.

VEEV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.9x
Enterprise Value/EBITDA48.1x
PEG Ratio4x

Price to Earnings Ratio vs Peers

How does VEEV's PE Ratio compare to its peers?

The above table shows the PE ratio for VEEV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average82.2x
DOCS Doximity
52.7x19.6%US$5.9b
SDGR Schrödinger
179x31.4%US$2.6b
MDRX Veradigm
11.2x29.4%US$1.3b
SLP Simulations Plus
86x18.0%US$900.4m
VEEV Veeva Systems
54.4x13.5%US$26.5b

Price-To-Earnings vs Peers: VEEV is good value based on its Price-To-Earnings Ratio (54.4x) compared to the peer average (82.2x).


Price to Earnings Ratio vs Industry

How does VEEV's PE Ratio compare vs other companies in the Global Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: VEEV is expensive based on its Price-To-Earnings Ratio (54.4x) compared to the Global Healthcare Services industry average (37.9x)


Price to Earnings Ratio vs Fair Ratio

What is VEEV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VEEV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio54.4x
Fair PE Ratio35.1x

Price-To-Earnings vs Fair Ratio: VEEV is expensive based on its Price-To-Earnings Ratio (54.4x) compared to the estimated Fair Price-To-Earnings Ratio (35.1x).


Share Price vs Fair Value

What is the Fair Price of VEEV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VEEV ($165.48) is trading below our estimate of fair value ($167.33)

Significantly Below Fair Value: VEEV is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VEEV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$165.48
US$207.38
+25.3%
11.5%US$275.00US$170.00n/a26
May ’24US$180.00
US$208.54
+15.9%
11.0%US$275.00US$170.00n/a26
Apr ’24US$183.79
US$208.81
+13.6%
10.9%US$275.00US$170.00n/a26
Mar ’24US$166.13
US$207.14
+24.7%
10.1%US$265.00US$170.00n/a26
Feb ’24US$173.37
US$209.40
+20.8%
10.2%US$265.00US$170.00n/a27
Jan ’24US$161.38
US$211.80
+31.2%
10.4%US$265.00US$170.00n/a27
Dec ’23US$191.42
US$212.36
+10.9%
9.9%US$257.00US$170.00n/a25
Nov ’23US$163.75
US$212.36
+29.7%
10.1%US$257.00US$170.00n/a25
Oct ’23US$164.88
US$219.75
+33.3%
10.2%US$275.00US$185.00n/a24
Sep ’23US$171.42
US$221.41
+29.2%
10.4%US$275.00US$185.00n/a22
Aug ’23US$224.29
US$231.00
+3.0%
12.6%US$275.00US$175.00n/a22
Jul ’23US$204.11
US$230.81
+13.1%
13.3%US$290.00US$175.00n/a21
Jun ’23US$167.84
US$244.05
+45.4%
15.0%US$300.00US$175.00n/a19
May ’23US$181.95
US$256.65
+41.1%
11.5%US$300.00US$200.00US$180.0020
Apr ’23US$216.76
US$258.35
+19.2%
11.2%US$300.00US$200.00US$183.7920
Mar ’23US$232.05
US$310.55
+33.8%
11.7%US$400.00US$230.00US$166.1322
Feb ’23US$238.10
US$315.09
+32.3%
9.7%US$400.00US$275.00US$173.3722
Jan ’23US$255.48
US$323.52
+26.6%
8.9%US$400.00US$280.00US$161.3821
Dec ’22US$272.12
US$339.80
+24.9%
7.7%US$400.00US$296.00US$191.4220
Nov ’22US$314.81
US$341.48
+8.5%
7.8%US$400.00US$296.00US$163.7521
Oct ’22US$287.28
US$341.05
+18.7%
7.8%US$400.00US$296.00US$164.8821
Sep ’22US$333.82
US$331.50
-0.7%
8.4%US$400.00US$270.00US$171.4220
Aug ’22US$332.71
US$334.55
+0.6%
8.5%US$400.00US$270.00US$224.2922
Jul ’22US$313.64
US$330.00
+5.2%
6.9%US$360.00US$270.00US$204.1122
Jun ’22US$285.51
US$330.00
+15.6%
6.9%US$360.00US$270.00US$167.8422
May ’22US$282.45
US$325.52
+15.2%
7.3%US$355.00US$250.00US$181.9523

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies